Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Jan;64(1):111–113. doi: 10.1136/ard.2003.018127

Prevalence and predictors of fragility fractures in systemic lupus erythematosus

C Yee 1, N Crabtree 1, J Skan 1, N Amft 1, S Bowman 1, D Situnayake 1, C Gordon 1
PMCID: PMC1755180  PMID: 15608308

Abstract

Objective: To establish the prevalence of reduced bone mineral density (BMD) and fractures, and risk factors for fractures, in a cross sectional study of a large cohort of patients with systemic lupus erythematosus (SLE).

Methods: All SLE patients willing to take part in the study had bone densitometry in 1999/2000 and completed a questionnaire on risk factors for osteoporosis and on drugs used. Accumulated damage was scored using the SLICC/ACR damage index (SDI). Only fractures occurring since the onset of SLE and unrelated to trauma were included, and the SDI score was modified to exclude osteoporotic fractures. Statistical analysis was by χ2 test, Fisher's exact test, and binary logistic regression.

Results: 242 patients were studied, median age 39.9 years (range 18 to 80), median disease duration 7.0 years (range 0 to 42). Of these, 123 (50.8%) had reduced BMD (T score <–1.0) and 25 (10.3%) were in the osteoporotic range (T score <–2.5). Fragility fractures had occurred in 22 patients (9.1%) since diagnosis of SLE. Of these, two (9.1%) had normal BMD and 20 (90.9%) had reduced BMD, while seven (31.8%) were within the osteoporotic range. Non-Afro-Caribbean race and exposure to prednisolone >10 mg daily were significantly associated with reduced BMD, while age and menopause were associated with osteoporosis. The risk factors for fractures were reduced BMD and age.

Conclusions: Reduced BMD, osteoporosis, and fragility fractures appear to be prevalent in patients with SLE. Steroids were not an independent risk factor for fractures, although their effect could be mediated through reduced bone mineral density.

Full Text

The Full Text of this article is available as a PDF (50.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
  2. Cohen S., Levy R. M., Keller M., Boling E., Emkey R. D., Greenwald M., Zizic T. M., Wallach S., Sewell K. L., Lukert B. P. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999 Nov;42(11):2309–2318. doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  3. Dhillon V. B., Davies M. C., Hall M. L., Round J. M., Ell P. J., Jacobs H. S., Snaith M. L., Isenberg D. A. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry. Ann Rheum Dis. 1990 Aug;49(8):624–626. doi: 10.1136/ard.49.8.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Formiga F., Moga I., Nolla J. M., Pac M., Mitjavila F., Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis. 1995 Apr;54(4):274–276. doi: 10.1136/ard.54.4.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gladman D. D., Goldsmith C. H., Urowitz M. B., Bacon P., Fortin P., Ginzler E., Gordon C., Hanly J. G., Isenberg D. A., Petri M. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000 Feb;27(2):373–376. [PubMed] [Google Scholar]
  6. Isenberg D. A., Gordon C., BILAG Group. British Isles Lupus Assessment Group From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus. 2000;9(9):651–654. doi: 10.1191/096120300672904669. [DOI] [PubMed] [Google Scholar]
  7. Kalla A. A., Fataar A. B., Jessop S. J., Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993 Dec;36(12):1726–1734. doi: 10.1002/art.1780361212. [DOI] [PubMed] [Google Scholar]
  8. Kipen Y., Buchbinder R., Forbes A., Strauss B., Littlejohn G., Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol. 1997 Oct;24(10):1922–1929. [PubMed] [Google Scholar]
  9. Melton III L. J., Marquez M. A., Achenbach S. J., Tefferi A., O'Connor M. K., O'Fallon W. M., Riggs B. L. Variations in bone density among persons of African heritage. Osteoporos Int. 2002 Jul;13(7):551–559. doi: 10.1007/s001980200072. [DOI] [PubMed] [Google Scholar]
  10. Pons F., Peris P., Guañabens N., Font J., Huguet M., Espinosa G., Ingelmo M., Muñoz-Gomez J., Setoain J. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol. 1995 Aug;34(8):742–746. doi: 10.1093/rheumatology/34.8.742. [DOI] [PubMed] [Google Scholar]
  11. Ramsey-Goldman R., Dunn J. E., Huang C. F., Dunlop D., Rairie J. E., Fitzgerald S., Manzi S. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999 May;42(5):882–890. doi: 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  12. Saag K. G., Emkey R., Schnitzer T. J., Brown J. P., Hawkins F., Goemaere S., Thamsborg G., Liberman U. A., Delmas P. D., Malice M. P. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292–299. doi: 10.1056/NEJM199807303390502. [DOI] [PubMed] [Google Scholar]
  13. Sels F., Dequeker J., Verwilghen J., Mbuyi-Muamba J. M. SLE and osteoporosis: dependence and/or independence on glucocorticoids. Lupus. 1996 Apr;5(2):89–92. doi: 10.1177/096120339600500202. [DOI] [PubMed] [Google Scholar]
  14. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  15. Van Staa T. P., Laan R. F., Barton I. P., Cohen S., Reid D. M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–3229. doi: 10.1002/art.11283. [DOI] [PubMed] [Google Scholar]
  16. Zonana-Nacach A., Barr S. G., Magder L. S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801–1808. doi: 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES